Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

British Journal of Haematology

Volumn 154, Issue 3, 2011, Pages 357-362

  Treon, Steven P ^a,b   Hanzis, Christina ^a   Manning, Robert J ^a   Ioakimidis, Leukothea ^a   Patterson, Christopher J ^a   Hunter, Zachary R ^a   Sheehy, Patricia ^a   Turnbull, Barry ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BioBridges   (United States)

Author keywords

CD20; Lymphoma; Maintenance; Rituximab; Waldenstrom Macroglobulinaemia

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; THALIDOMIDE;

ADULT; ARTHRALGIA; ARTICLE; BRONCHITIS; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; ENCEPHALITIS; FEBRILE NEUTROPENIA; HEMATOCRIT; HERPES ZOSTER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEUTROPENIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINUSITIS; SKIN INFECTION; SYNCOPE; UPPER RESPIRATORY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; HEMATOCRIT; HUMANS; IMMUNOGLOBULINS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 80955178796     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08750.x     Document Type: Article

References (25)

1. Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J. & Anagnostopoulos, N. (2002) Treatment of Waldenstrom's macroglobulinemia with rituximab. Journal of Clinical Oncology, 20, 2327-2333.
2. Dimopoulos, M.A., Gertz, M.A., Kastritis, E., Garcia-Sanz, R., Kimby, E.K., Leblond, V., Fermand, J.P., Merlini, G., Morel, P., Morra, E., Ocio, E.M., Owen, R., Ghobrial, I.M., Seymour, J., Kyle, R.A. & Treon, S.P. (2009) Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. Journal of Clinical Oncology, 27, 120-126.
3. Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317-324.
4. Forstpointner, R., Unterhalt, M., Dreyling, M., Böck, H.P., Repp, R., Wandt, H., Pott, C., Seymour, J.F., Metzner, B., Hänel, A., Lehmann, T., Hartmann, F., Einsele, H. & Hiddemann, W. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, 4003-4008.
5. Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H. & Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leukemia and Lymphoma, 45, 2047-2055.
6. Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab with follicular lymphoma significantly increases event free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103, 4416-4423.
7. Hainsworth, J.D., Burris, III, H.A., Morrissey, L.H., Litchy, S., Scullin, Jr, D.C., Bearden, III, J.C. & Greco, F.A. (2001) Rituximab as first-line and maintenance therapy for patients (Pts) with indolent non-hodgkin's lymphoma (NHL). Proceedings American Society Clinical Oncology, 20, 1175.
8. Hainsworth, J.D., Litchy, S., Burris, III, H.A., Scullin, Jr, D.C., Corso, S.W., Yardley, D.A., Morrissey, L. & Greco, F.A. (2002) Rituximab as first line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. Journal of Clinical Oncology, 20, 4261-4267.
9. Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E. & Greco, F.A. (2003) Single agent rituximab as first line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 1746-1751.
10. Hainsworth, J.D., Litchy, S., Shaffer, D.W., Lackey, V.L., Grimaldi, M. & Greco, F.A. (2009) Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression. Journal of Clinical Oncology, 23, 1088-1095.
11. Hunter, Z.R., Manning, R.J., Hanzis, C., Ciccarelli, B.T., Ioakimidis, L., Patterson, C.J., Lewicki, M.C., Tseng, H., Gong, P., Liu, X., Zhou, Y., Yang, G., Sun, J., Xu, L., Sheehy, P., Morra, M. & Treon, S.P. (2010) IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. Haematologica, 95, 470-475.
12. Kahl, B.S., Williams, M.E., Hong, F., Gascoyne, R. & Horning, S.J. (2007) Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab Extended Schedule or Re-Treatment Trial (RESORT). Blood (ASH Annual Meeting Abstracts), 110, 1002A.
13. Kimby, E., Treon, S.P., Anagnostopoulos, A., Dimopoulos, M., Garcia-Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R., Stone, M. & Bladé, J. (2006) Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clinical Lymphoma & Myeloma, 6, 380-383.
14. van Oers, M.H.J., Van Glabbeke, M., Teodorovic, I., Rozewicz, C., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E. & Hagenbeek, A. (2004) Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabthera®) in Remission Induction and Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: a Phase III Randomized Intergroup Clinical Trial. Blood (ASH Annual Meeting Abstracts), 104, 41A.
15. van Oers, M.H., Van Glabbeke, M., Giurgea, L., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., van t Veer, M., Vranovsky, A., Holte, H. & Hagenbeek, A. (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study. Journal of Clinical Oncology, 28, 2853-2858.
16. Owen, R.G., Treon, S.P., Al-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. & Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenström's macroglobulinemia: consensus Panel Recommendations from the Second International Workshop on Waldenström's macroglobulinemia. Seminars in Oncology, 30, 110-115.
17. Taverna, C.J., Bassi, S., Hitz, F., Mingrone, W., Pabst, T., Cevreska, L., del Giglio, A., Vorobiof, D.A., Simcock, M. & Ghielmini, M. (2009) First results of long term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. Journal of Clinical Oncology, 27, 442S.
18. Treon, S.P. (2009) How I treat Waldenstrom macroglobulinemia. Blood, 114, 2375-2385.
19. Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A.I., Clark, B., Lucas, M.S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K.C. & Byrd, J.C. (2001) CD20 directed serotherapy induces responses and facilitates hematological recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy, 24, 272-279.
20. Treon, S.P., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Branagan, A.R., Anderson, K.C. & Frankel, S.R. (2005) Extended rituximab therapy in Waldenström's Macroglobulinemia. Annals of Oncology, 16, 132-138.
21. Treon, S.P., Gertz, M.A., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A.R., Garcia-Sanz, R., Johnson, S., Kimby, E., Leblond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R. & Stone, M.J. (2006) Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia. Blood, 107, 3442-3446.
22. Treon, S.P., Branagan, A.R., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Turnbull, B., Wasi, P., Emmanouilides, C., Frankel, S.R., Lister, A., Morel, P., Matous, J., Gregory, S.A. & Kimby, E. (2009a) Long term outcomes to fludarabine and rituximab in Waldenstrom's macroglobulinemia. Blood, 113, 3673-3678.
23. Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy, P., Nelson, M., Willen, M., Matous, J., Mattern, II, J., Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L. & Ghobrial, I.M. (2009b) Primary therapy of Waldenstrom's Macroglobulinemia with Bortezomib, Dexamethasone and Rituximab: results of WMCTG Clinical Trial 05-180. Journal of Clinical Oncology, 27, 3830-3835.
24. Treon, S.P., Yang, G., Hanzis, C., Ioakimidis, L., Verselis, S.J., Fox, E.A., Xu, L., Hunter, Z.R., Tseng, H., Manning, R.J., Patterson, C.J. & Sheehy, P. (2011) Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. British Journal of Haematology, Epub ahead of print. doi:.
25. Wenger, M.K., Foa, R., Arcaini, L., Vranovský, A., Ivanova, V., Van Hazel, G.A., Kurtovic, S., Durán, S., Gamba, E. & Thurley, D. (2008) Safety in patients receiving maintenance rituximab for follicular lymphoma: results from the phase IIIb MAXIMA trial. Journal of Clinical Oncology (ASCO Meeting Abstracts), 26, 479S.